A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label trial to estimate the concentrations of brentuximab vedotin in
relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large
cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab
vedotin + rifampicin.